Avicanna Beheer

Beheer criteriumcontroles 3/4

De CEO Avicanna is Aras Azadian, benoemd in Jan2016, heeft een ambtstermijn van 8.83 jaar. De totale jaarlijkse vergoeding van { bedraagt CA$ 336.01K, bestaande uit 26.3% salaris en 73.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 4.01% van de aandelen van het bedrijf, ter waarde € 835.25K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.9 jaar en 3.4 jaar.

Belangrijke informatie

Aras Azadian

Algemeen directeur

CA$336.0k

Totale compensatie

Percentage CEO-salaris	26.3%
Dienstverband CEO	8.8yrs
Eigendom CEO	4.0%
Management gemiddelde ambtstermijn	1.9yrs
Gemiddelde ambtstermijn bestuur	3.4yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Aras Azadian's beloning veranderd ten opzichte van Avicanna's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-CA$7m
Jun 30 2024	n/a	n/a	-CA$7m
Mar 31 2024	n/a	n/a	-CA$7m
Dec 31 2023	CA$336k	CA$88k	-CA$9m
Sep 30 2023	n/a	n/a	-CA$12m
Jun 30 2023	n/a	n/a	-CA$14m
Mar 31 2023	n/a	n/a	-CA$16m
Dec 31 2022	CA$486k	CA$161k	-CA$15m
Sep 30 2022	n/a	n/a	-CA$16m
Jun 30 2022	n/a	n/a	-CA$16m
Mar 31 2022	n/a	n/a	-CA$15m
Dec 31 2021	CA$244k	CA$127k	-CA$17m
Sep 30 2021	n/a	n/a	-CA$24m
Jun 30 2021	n/a	n/a	-CA$29m
Mar 31 2021	n/a	n/a	-CA$34m
Dec 31 2020	CA$358k	CA$110k	-CA$33m
Sep 30 2020	n/a	n/a	-CA$25m
Jun 30 2020	n/a	n/a	-CA$24m
Mar 31 2020	n/a	n/a	-CA$21m
Dec 31 2019	CA$608k	CA$240k	-CA$22m
Sep 30 2019	n/a	n/a	-CA$18m
Jun 30 2019	n/a	n/a	-CA$14m
Mar 31 2019	n/a	n/a	-CA$11m
Dec 31 2018	CA$150k	CA$150k	-CA$7m
Sep 30 2018	n/a	n/a	-CA$5m
Dec 31 2017	CA$180k	CA$150k	-CA$3m

Compensatie versus markt: De totale vergoeding ($USD 238.87K ) Aras } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 474.54K ).

Compensatie versus inkomsten: De vergoeding van Aras is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Aras Azadian

8.8yrs

Tenure

CA$336,008

Compensatie

Mr. Aras Azadian, M. Mgmt, Msc Management, B.Econ, MBA, is a Co-Founder of Avicanna Inc. He serves as Chief Executive Officer and Director since November 25, 2016 of Avicanna Inc. and served as its Chairma...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Aras Azadian	Co-Founder	8.8yrs	CA$336.01k	4.01% € 835.2k
Phillip Cardella	Chief Financial Officer	1.9yrs	CA$254.02k	0.63% € 130.4k
Ivana Maric	Executive Vice President of Marketing	no data	CA$249.08k	geen gegevens
Stephen Kim	Chief Legal Officer & General Counsel of Avicanna USA Inc.	1.9yrs	CA$396.48k	geen gegevens
Karolina Urban	Executive Vice President of Scientific & Medical Affairs	1.4yrs	CA$255.87k	geen gegevens
Arash Moghani	Executive Vice President of Operations & Technology	no data	geen gegevens	geen gegevens
Ingrid Diaz	VP, Assistant General Counsel & Corporate Compliance Officer	1.4yrs	geen gegevens	geen gegevens
Enric Pujol	Vice President of People	no data	geen gegevens	geen gegevens
Carlos Enrique Muete	SVP of Clinical Development	no data	geen gegevens	geen gegevens

1.9yrs

Gemiddelde duur

Ervaren management: Het managementteam van 0NN wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.9 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Aras Azadian	Co-Founder	8yrs	CA$336.01k	4.01% € 835.2k
Sheldon Inwentash	Member of Business Advisory Board	no data	geen gegevens	5.54% € 1.2m
Paul Fornazzari	Independent Director	less than a year	CA$12.31k	0.91% € 190.0k
Daniel Sauder	Member of Global Scientific Advisory Board	no data	geen gegevens	geen gegevens
Giancarlo Char	Director	6.1yrs	CA$88.30k	0.63% € 131.5k
Aline Masuda	Member of Business Advisory Board	no data	geen gegevens	geen gegevens
Mauricio Torres-Pradilla	Member of Global Scientific Advisory Board	no data	geen gegevens	geen gegevens
Humberto Reynales	Member of International Scientific Advisory Board	no data	geen gegevens	geen gegevens
Max Jones	Member of Global Scientific Advisory Board	no data	geen gegevens	geen gegevens
John McVicar	Independent Director	3.4yrs	CA$118.75k	0.45% € 93.0k
Eileen McCormack	Independent Director	2.8yrs	CA$110.18k	0.25% € 51.9k
Al Harrington	Member of Business Advisory Board	no data	geen gegevens	geen gegevens

3.4yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 0NN wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.4 jaar).

Avicanna Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Avicanna Inc., Annual General Meeting, Jul 10, 2024

Insider recently bought €169k worth of stock

Less than half of directors are independent

Avicanna Announces Appointment of Paul Fornazzari to Board of Directors

Avicanna Inc. Announces Retirement of Chandra Panchal, PhD from the Board of Directors

Insider recently bought €90k worth of stock

Recent updates

Third quarter 2024 earnings released: CA$0.008 loss per share (vs CA$0.016 loss in 3Q 2023)

Avicanna Inc. announced that it has received CAD 0.80001 million in funding

Avicanna Inc. announced that it has received CAD 1.986208 million in funding

Second quarter 2024 earnings released: CA$0.021 loss per share (vs CA$0.021 loss in 2Q 2023)

Avicanna Announces United States Patent and Trademark Office Issuance of Patent SEDDS Technology

Avicanna Inc., Annual General Meeting, Jul 10, 2024

Insider recently bought €169k worth of stock

First quarter 2024 earnings released: CA$0.011 loss per share (vs CA$0.033 loss in 1Q 2023)

Avicanna Inc. Announces Results of Study in Patients with Epidermolysis Bullosa

Avicanna Inc. announced that it has received CAD 2.125584 million in funding

Avicanna Inc. Announces Completion of Topical Gel Observational Real-World Evidence Study

Full year 2023 earnings released: CA$0.10 loss per share (vs CA$0.25 loss in FY 2022)

Avicanna Inc Announces the Canadian Launch of 10% CBD (THC Free) Proprietary Formulation

Avicanna Inc. to Report Fiscal Year 2023 Results on Apr 01, 2024

Avicanna Inc. Obtains Its First Indication-Specific Drug Registration with Trunerox

Avicanna Inc. announced that it has received CAD 0.888128 million in funding

Less than half of directors are independent

Third quarter 2023 earnings released: CA$0.016 loss per share (vs CA$0.048 loss in 3Q 2022)

Avicanna Announces Appointment of Paul Fornazzari to Board of Directors

Avicanna Inc. to Report Q3, 2023 Results on Nov 14, 2023

Avicanna Inc. Provides Update on the Successful Launch of MyMedi.ca

Avicanna Inc. Announces Retirement of Chandra Panchal, PhD from the Board of Directors

Second quarter 2023 earnings released: CA$0.021 loss per share (vs CA$0.08 loss in 2Q 2022)

Avicanna Inc. announced that it has received CAD 1.455 million in funding

Avicanna Inc. (TSX:AVCN) completed the acquisition of Medical Cannabis by Shoppers Drug Mart Inc from Shoppers Drug Mart Inc.

Avicanna Inc. (TSX:AVCN) entered into definitive Asset Purchase Agreement to acquire Medical Cannabis by Shoppers Drug Mart Inc from Shoppers Drug Mart Inc. for CAD 2.6 million.

First quarter 2023 earnings released: CA$0.033 loss per share (vs CA$0.02 loss in 1Q 2022)

Insider recently bought €90k worth of stock

Avicanna LATAM S.A.S. Announces Step Down of Lucas Nosiglia as President, Effective January 31, 2023

Avicanna Inc. announced that it has received CAD 1.769097 million in funding

Avicanna and Santé Cannabis Initiate Real-World Evidence Study on Musculoskeletal Pain and Inflammation with the Rho Phytotm Cbg Transdermal Gel Topical Product

Avicanna Inc. Commercializes ‘Influid’, a Proprietary Water-soluble technology in the Canadian Market

Insider recently bought €388k worth of stock

Third quarter 2022 earnings released: CA$0.048 loss per share (vs CA$0.065 loss in 3Q 2021)

Third quarter 2022 earnings released: CA$0.048 loss per share (vs CA$0.065 loss in 3Q 2021)

Avicanna Inc. announced that it has received CAD 0.626763 million in funding

Avicanna Files Complete Patent Specifications Relating to A Novel Cannabinoid Formulation for Reducing Incidence of Seizures and Sudden Unexpected Death in Epilepsy

Avicanna Introduces a New Medical Cannabis Education Online Portal, "Avicenna Academy" for Health Care Professionals

Assad Kazeminy Retires as Director of Avicanna Inc

Second quarter 2022 earnings released: CA$0.08 loss per share (vs CA$0.067 loss in 2Q 2021)

Avicanna Inc. announced that it has received CAD 2.782302 million in funding

Avicanna Inc., Annual General Meeting, Aug 31, 2022

An unknown buyer acquired 63 percent stake in Sativa Nativa S.A.S. from Avicanna Inc. (TSX:AVCN) for CAD 0.81 million.

Forecast to breakeven in 2024

First quarter 2022 earnings released: CA$0.02 loss per share (vs CA$0.085 loss in 1Q 2021)

Avicanna Inc. Announces Chief Financial Officer Changes

Avicanna Inc. announced that it has received CAD 1.473826 million in funding from Ei.Ventures, Inc.

Full year 2021 earnings released: CA$0.41 loss per share (vs CA$1.12 loss in FY 2020)

Avicanna Inc. announced that it has received CAD 2.523568 million in funding

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd